168. エーラス・ダンロス症候群 Ehlers-Danlos syndrome Clinical trials / Disease details


臨床試験数 : 13 薬物数 : 21 - (DrugBank : 11) / 標的遺伝子数 : 11 - 標的パスウェイ数 : 103

  
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05463679
(ClinicalTrials.gov)
January 20246/4/2022Investigate Efficacy, Safety, and Pharmacokinetics of Enzastaurin for the Prevention of Arterial Events in Patients With Vascular Ehlers-Danlos Syndrome.A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Enzastaurin for the Prevention of Arterial Events in Patients With Vascular Ehlers-Danlos Syndrome (vEDS) Confirmed With COL3A1 Mutations, Followed by an Open Label Extension (OLE)Vascular Ehlers-Danlos SyndromeDrug: Enzastaurin;Drug: PlaceboAytu BioPharma, Inc.ParexelSuspended18 Years60 YearsAll260Phase 3United States
2NCT04890431
(ClinicalTrials.gov)
June 20216/5/2021Impact of Oxygen Therapy on Fatigue in Patients With Hypermobile-type Ehlers-Danlos SyndromeImpact of Oxygen Therapy on Fatigue in Patients With Hypermobile-type Ehlers-Danlos Syndrome: a Randomised Double-blind Placebo-controlled StudyEhlers-Danlos SyndromeDrug: Oxygen;Drug: PlaceboHospital St. Joseph, Marseille, FranceNULLNot yet recruiting18 YearsN/AAll82Phase 4NULL
3NCT02597361
(ClinicalTrials.gov)
January 201623/10/2015Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome (ARCADE)Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome: a Double Blind, Randomized, Placebo Controlled, Multicenter Trial.Ehlers-Danlos Syndrome, Vascular TypeDrug: Irbesartan;Drug: PlaceboAssistance Publique - Hôpitaux de ParisMinistry of Health, FranceCompleted18 Years70 YearsAll61Phase 3France
4NCT00190411
(ClinicalTrials.gov)
October 200313/9/2005Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular TypePrevention of Vascular Complications by BetaBlocker Treatment in Vascular Ehlers-Danlos SyndromeEHLERS-DANLOS SYNDROME, TYPE IV, AUTOSOMAL DOMINANT;CHROMOSOME 2q31.2 DELETION SYNDROMEDrug: celiprolol;Drug: ControlAssistance Publique - Hôpitaux de ParisAventis PharmaceuticalsCompleted15 Years65 YearsBoth54Phase 4France
5EUCTR2021-006574-23-NL
(EUCTR)
25/04/2022A study to investigate the efficacy, safety, and pharmacokinetics (PK) of enzastaurin for the prevention of arterial events in patients with vEDS confirmed with COL3A1 mutationsA multicenter, randomized, double-blind, placebo-controlled study of enzastaurin for the prevention of arterial events in patients with vascular Ehlers-Danlos Syndrome (vEDS) confirmed with COL3A1 mutations, followed by an open label extension (OLE) - PREVEnt (Prevention of Rupture with Enzastaurin in Vascular Ehlers-Danlos Syndrome Trial) vascular Ehlers-Danlos Syndrome (vEDS) confirmed with COL3A1 mutations
MedDRA version: 20.0;Level: PT;Classification code 10014316;Term: Ehlers-Danlos syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Product Name: Enzastaurin
Product Code: AR101
INN or Proposed INN: Enzastaurin
Other descriptive name: ENZASTAURIN HYDROCHLORIDE
Aytu BioPharma, Inc.NULLNAFemale: yes
Male: yes
260Phase 3France;United States;Belgium;Netherlands;United Kingdom;Sweden